延华智能(002178) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥120,749,404.48, a decrease of 25.62% compared to ¥162,345,419.56 in the same period last year[3] - The net profit attributable to shareholders was -¥8,623,131.08, an improvement of 38.09% from -¥13,928,887.42 year-on-year[3] - The net cash flow from operating activities was -¥88,921,716.94, a decline of 39.86% compared to -¥63,576,911.93 in the previous year[3] - The weighted average return on equity was -1.52%, an improvement of 0.97% from -2.49% in the previous year[3] - Total operating revenue for Q1 2022 was CNY 120,749,404.48, a decrease of 25.7% compared to CNY 162,345,419.56 in the same period last year[24] - Net loss for Q1 2022 was CNY 8,554,673.15, an improvement from a net loss of CNY 17,792,425.65 in Q1 2021[25] - Operating profit for Q1 2022 was CNY -7,971,727.88, compared to CNY -17,320,853.23 in the previous year, indicating a narrowing of losses[25] Cash Flow - Cash inflow from operating activities was CNY 143,073,041.07, down 43.3% from CNY 252,359,593.62 in the same quarter last year[27] - Cash outflow for purchasing goods and services was CNY 155,071,711.25, a decrease from CNY 212,683,481.56 year-over-year[27] - The net cash flow from operating activities was -88,921,716.94 CNY, compared to -63,576,911.93 CNY in the previous year[28] - The total cash inflow from investment activities was 1,061,933.03 CNY, down from 21,188,932.66 CNY year-over-year[28] - The net cash flow from investment activities was -27,764,010.75 CNY, contrasting with a positive 11,549,419.18 CNY in the same period last year[28] - The cash inflow from financing activities totaled 52,500,000.00 CNY, compared to 50,573,215.72 CNY in the previous year[28] - The net cash flow from financing activities was -6,069,730.59 CNY, an improvement from -13,224,191.52 CNY year-over-year[28] - The company reported a significant increase in cash outflow from operating activities, totaling 231,994,758.01 CNY compared to 315,936,505.55 CNY last year[28] - The company experienced a decrease in cash flow due to higher operational costs and lower investment returns[28] - The company aims to improve cash flow management and explore new investment opportunities in the upcoming quarters[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,656,765,492.45, down 6.41% from ¥1,770,309,347.04 at the end of the previous year[3] - The company's cash and cash equivalents decreased to CNY 272,729,205.69 from CNY 392,853,687.92, representing a decline of approximately 30.59%[20] - Accounts receivable increased to CNY 363,372,416.43 from CNY 352,812,171.70, showing a growth of about 2.99%[20] - The total current liabilities decreased to CNY 915,182,247.03 from CNY 1,021,904,527.06, a reduction of approximately 10.43%[21] - Total liabilities as of Q1 2022 were CNY 926,709,205.75, a decrease from CNY 1,034,198,387.19 in the previous year[22] - Total equity attributable to shareholders of the parent company was CNY 562,996,134.66, down from CNY 571,384,459.72 year-over-year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 89,426[9] - The top three shareholders held a combined 36.27% of the shares, with Huarong (Tianjin Free Trade Zone) Investment Co., Ltd. holding 17.41%[9] - The first major shareholder, Huarong Jintou, plans to transfer 89,019,125 shares, accounting for 12.50% of the total share capital[11] Research and Development - The company's R&D expenses decreased by 46.08% compared to the previous year, primarily due to reduced investment in medical software development by subsidiaries[6] - Research and development expenses for Q1 2022 were CNY 7,340,575.24, down 46.0% from CNY 13,614,490.15 in the previous year[25] Other Information - The company provided a guarantee for its subsidiary, Shanghai Dongfang Yanhua, for a maximum debt amount of CNY 10 million[17] - The company did not conduct an audit for the first quarter report[29]